Axsome’s Investigational Narcolepsy Compound Gets FDA Breakthrough Therapy Designation
The Breakthrough Therapy designation for AXS-12 was supported by the positive results from the Phase 2 CONCERT study.
Read MoreThe Breakthrough Therapy designation for AXS-12 was supported by the positive results from the Phase 2 CONCERT study.
Read MoreSleep apnea is associated with a variety of cardiovascular conditions and outcomes, but the strongest associations are with high blood pressure, arrhythmias, and heart failure, reports Today’s Geriatric Medicine.
Read MoreAG Industries’ engineers worked closely with the company’s respiratory customers to quickly identify a filtration solution that circumvented bottlenecks in the supply chain caused by the COVID-19 crisis.
Read MoreThe AASM supports a switch to permanent standard time, explaining in a statement that standard time more closely aligns with the body’s internal clock.
Read MoreAn athlete has a greater opportunity for optimal performance when the timing of an activity is synchronized with the body’s circadian clock.
Read More